Key result
Oral administration of RB150 produced a marked dose-dependent reduction in blood pressure in hypertensive DOCA-salt rats, with an ED50 in the 1-mg/kg range.
Why the study?
Does oral administration of the aminopeptidase A inhibitor RB150 reduce blood pressure in hypertensive rats?
Population
Conscious DOCA-salt rats (hypertensive model) and normotensive rats
Comparison
Oral administration of RB150 vs Normotensive rats / untreated baseline
Design
Preclinical
Follow-up
Several hours
Authors
Loading...
Hypothesis-generating for aminopeptidase A inhibition in hypertension; requires human trials before any clinical consideration.
Does oral administration of the aminopeptidase A inhibitor RB150 reduce blood pressure in hypertensive rats?
Oral administration of the aminopeptidase A inhibitor RB150 reduces blood pressure in a hypertensive rat model, suggesting a potential new class of centrally active antihypertensive agents.
Bodineau et al. (2008) studied Hypertension. RB150 (aminopeptidase A inhibitor) vs. Normotensive rats was evaluated on Blood pressure reduction. Oral administration of RB150 produced a marked dose-dependent reduction in blood pressure in hypertensive DOCA-salt rats, with an ED50 in the 1-mg/kg range.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: